title: Onycholysis of the finger and toenails following the application of high-dose oral etoposide (1250 mg/m2) given as 200- and 150-mg single doses from days 1-10 every 3 weeks.
authors.forename: A
authors.initials: A
authors.lastname: Obermair
authors.forename: N
authors.initials: N
authors.lastname: Vavra
authors.forename: C
authors.initials: C
authors.lastname: Kurz
authors.forename: H
authors.initials: H
authors.lastname: Helmer
authors.forename: P
authors.initials: P
authors.lastname: Sevelda
authors.forename: K
authors.initials: K
authors.lastname: Pehamberger
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005385:Fingers; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D009260:Nail Diseases / Q000139:chemically induced*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D014034:Toes
chemical_list: D015251:Epirubicin; D005047:Etoposide; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide; D002945:Cisplatin